Effects of Fuzheng Xiaoai decoction joint tamoxifen on serum sex hormone and endometrial thickness with breast cancer / 中国生化药物杂志

Objective To analyze the effects of Fuzheng Xiaoai decoction joint tamoxifen on serum sex hormone and endometrial thickness with breast cancer.Methods 124 patients with breast cancer were divided into control group and research group by lot drawing method, all as 62 cases, treated with the same surgery, control group was treated with tamoxifen, research group was treated with Fuzheng Xiaoai decoction based on control group, the sex hormones, endometrial thickness, tumor markers, immune function and complications were compared between two groups.Results The prolactin (PRL), progesterone (P), estradiol (E2) of research group were all lower than control group, the difference were statistically significant (P<0.05).The endometrial thickness of research group [(8.61+1.07) mm]was lower than the control group [(9.74+1.21) mm](P<0.05).The tumor markers, immune function of research group were better than that of control group (P<0.05).The complications was no difference between two groups. Conclusion Fuzheng Xiaoai decoction joint tamoxifen can regulation the serum levels of sex hormone, relieve tamoxifen-induced endometrial thickening, can improve tumor markers and immune function .

Epirubicin hydrochloride combined with capecitabine tablets on serum OPN,VEGF-C and its efficacy in triple-negative breast cancer / 中国生化药物杂志

Objective To explore epirubicin hydrochloride combined with capecitabine tablets on serum levels of osteopontin (OPN), vascular endothelial growth factor C ( VEGF-C) and its efficacy in the treatment of patients with triple-negative breast cancer.Methods 80 cases triple-negative breast cancer were selected, randomly divided into two groups, 40 cases in each group.The control group were given epirubicin treatment, joint group on the basis of the control group were combined with capecitabine, 21 days for a course of treatment, four courses of treatment.The serum levels of OPN and VEGF-C pre-and post-treatment were detected, the efficacy and adverse reactions were observed.Results Compared with before treatment, the serum levels of OPN and VEGF-C in two groups were lower post-treatment(P<0.05).Compared with control group, the OPN and VEGF-C levels in joint group were lower (P<0.05), the efficacy was higher and the adverse reaction was lower (P<0.05).Conclusion The epirubicin hydrochloride combined with capecitabine tablets could reduce serum OPN and VEGF-C levels in the treatment of patients with triple-negative breast cancer, with high security.